RxDoctor Payments Data

Andres Ruiz, MD

Cardiovascular Disease · Delray Beach, FLNPI 1932262698

Payments from drug & device makers

$137,267in general payments, 2019–2025

Across 1,020 payments — averaging $134.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$119K
  • Actelion Pharmaceuticals US, Inc.$3K
  • Johnson & Johnson$1K
  • Amgen$1K
  • Penumbra, Inc.$1K
  • AstraZeneca$1K
  • plus $11K from 53 others

What the payments were for

  • Travel & lodging$9635%
  • Food & beverage$18,97594%
  • Education$2911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott102$118,589
Actelion Pharmaceuticals US, Inc.96$2,573
Johnson & Johnson122$1,401
Amgen80$1,246
Penumbra, Inc.11$1,212
AstraZeneca69$1,162
Abiomed25$882
Philips North America LLC5$856
Novartis41$678
Amarin Pharma, Inc.37$675
Merck33$615
Boehringer Ingelheim28$582
Pfizer39$574
E.r. Squibb & Sons, L.L.C.43$508
Sanofi-aventis U.S. LLC24$488
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)32$359
Kestra Medical Technology Services, Inc.13$335
Esperion Therapeutics, Inc.20$314
Boston Scientific16$311
Heartflow, Inc.5$296
Cvrx, Inc.26$280
Kowa Pharmaceuticals America, Inc.14$261
Lundbeck LLC12$229
United Therapeutics Corporation11$224
Cardiva Medical, Inc.10$221
Medtronic(2 entities)9$207
Alnylam Pharmaceuticals Inc.9$191
Bayer8$152
Biotronik Inc.5$144
Chiesi USA, Inc.8$127
Impulse Dynamics (USA) Inc.2$120
Kiniksa Pharmaceuticals International, PLC4$117
Bridgebio Pharma, Inc.6$109
Kiniksa Pharmaceuticals, Ltd.5$105
Bolton Medical Inc1$99
Novo Nordisk5$97
Bard Peripheral Vascular, Inc.2$80
Agepha Pharma FZ LLC4$80
Tactile Systems Technology Inc5$80
Akcea Therapeutics, Inc.3$68
Lexicon Pharmaceuticals, Inc.3$63
Regeneron Healthcare Solutions, Inc.4$60
BD2$60
Shockwave Medical, Inc3$46
GE HealthCare2$44
Cardiovascular Systems Inc.1$44
Stryker1$36
Arbor Pharmaceuticals, Inc.2$35
Edwards Lifesciences1$34
Inari Medical, Inc.1$29
Mindray DS USA, Inc.1$27
ZOLL Circulation Inc2$27
Atricure, Inc.1$27
Gilead1$18
Cardinal Health 200 LLC1$16
Biocompatibles, Inc.1$16
G Medical Diagnostic Services, Inc.1$14
Asahi Intecc USA, Inc.1$14
Acera Surgical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,267 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,841,705
Medicare patients
2,260
Services billed
15,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$460,455
OpsumitMacitentan28$423,890
UptraviSelexipag17$355,099
XareltoRivaroxaban263$321,682
EntrestoSacubitril/Valsartan116$156,586
Repatha SureclickEvolocumab113$133,714
BrilintaTicagrelor52$49,296
MultaqDronedarone Hcl27$36,492
FarxigaDapagliflozin Propanediol24$36,249
Orenitram ErTreprostinil Diolamine14$30,897
VerquvoVericiguat27$28,091
JardianceEmpagliflozin28$27,831
Repatha SyringeEvolocumab28$27,167
NexlizetBempedoic Acid/Ezetimibe13$12,761
Diltiazem 12hr ErDiltiazem Hcl65$11,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$2,573$778,98945 claims
PfizerEliquis$574$460,455368 claims
Johnson & JohnsonXarelto$1,401$321,682263 claims
NovartisEntresto$678$156,586116 claims
AstraZenecaBrilinta, Farxiga$1,162$85,54576 claims
Sanofi-aventis U.S. LLCMultaq$488$36,49227 claims
MerckVerquvo$615$28,09127 claims
Boehringer IngelheimJardiance$582$27,83128 claims
Esperion Therapeutics, Inc.Nexlizet$314$12,76113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →